BGM Group Ltd. - Class A Ordinary Shares (BGM)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Aug 19, 2026Investment Snapshot
- Trading 92% below Graham Number ($4.34) — significant margin of safety
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -5.1%
- Revenue growing at 51% annually
BGM Group Ltd. - Class A Ordinary Shares (BGM) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $13 million . Key value metrics: P/E ratio 2.2, P/B ratio 0.03, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
BGM Group Ltd. - Class A Ordinary Shares — Fundamental Analysis Summary
BGM Group Ltd. - Class A Ordinary Shares (BGM) is trading 92% below its Graham Number of $4.34 — a significant margin of safety by Benjamin Graham's standard. The stock carries a low trailing P/E ratio of 2.2x.
On financial health, BGM shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -5.1% (sector average: -20.1%), and minimal leverage with a debt-to-equity ratio of 0.13.
StockPik's composite Value Score for BGM is 53/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BGM reports a thin gross margin of 16.6% (sector average: 37.4%) and a negative operating margin of -33.2%.
BGM shows revenue growing at 51% year-over-year, with earnings declining at 1,282%.